Erratum to: Dig Dis Sci (2017) 62:1305–1312 DOI 10.1007/s10620-017-4511-4
The article Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months, written by F. Argüelles-Arias, M. F. Guerra Veloz, R. Perea Amarillo, A. Vilches-Arenas, L. Castro Laria, B. Maldonado Pérez, D. Chaaro, A. Benítez Roldán, V. Merino, G. Ramírez, A. Caunedo Álvarez and M. Romero Gómez, was originally published Online First without open access. After publication in volume 62, issue 5, page 1305–1312, the author decided to opt for Open Choice and to make the article an open access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license and any changes made are indicated.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s10620-017-4511-4.
Rights and permissions
About this article
Cite this article
Argüelles-Arias, F., Guerra Veloz, M.F., Perea Amarillo, R. et al. Erratum to: Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. Dig Dis Sci 62, 2203 (2017). https://doi.org/10.1007/s10620-017-4657-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-017-4657-0